Helicobacter pylori is a spiral-shaped, flagellated, microaerophilic Gram-negative bacillus discovered at the beginning of the 1980s that causes gastritis, peptic ulcers and stomach cancer in humans. So what’s new?
Helicobacter pylori infection: what’s new. Current Opinion in Infectious Diseases, 25(3): 337–344
Helicobacter pylori colonizes the human stomach causing gastritis and severe diseases including gastric cancer. One of the most dangerous H. pylori factors, CagA, has been investigated in relation to gastric cancer: recently this relationship was strongly reinforced by the finding that CagA interacts with the tumor suppressor apoptosis-stimulating protein of p53-2 (ASPP2), promoting p53 degradation. Treg have been proposed to be involved in H. pylori infection and gastric disease: recent findings suggest that Treg-induced tolerance, rather than immunity to H. pylori, may result in less severe disease. The eradication rates achieved with the standard triple therapy dropped below 80%, mainly due to antibiotic resistance, while no vaccines are currently licensed; new treatments/regimens were subjected to clinical trials, in some cases strongly increasing the eradication rates.